JP2016525502A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016525502A5 JP2016525502A5 JP2016519574A JP2016519574A JP2016525502A5 JP 2016525502 A5 JP2016525502 A5 JP 2016525502A5 JP 2016519574 A JP2016519574 A JP 2016519574A JP 2016519574 A JP2016519574 A JP 2016519574A JP 2016525502 A5 JP2016525502 A5 JP 2016525502A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- acid sequence
- amino acid
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 30
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 208000034799 Tauopathies Diseases 0.000 claims 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 210000002569 neuron Anatomy 0.000 claims 3
- 230000007466 Aβ secretion Effects 0.000 claims 2
- 230000008499 blood brain barrier function Effects 0.000 claims 2
- 210000001218 blood-brain barrier Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 210000004897 n-terminal region Anatomy 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361833355P | 2013-06-10 | 2013-06-10 | |
| US61/833,355 | 2013-06-10 | ||
| PCT/US2013/055203 WO2014028777A2 (en) | 2012-08-16 | 2013-08-15 | Methods of treating a tauopathy |
| USPCT/US2013/055203 | 2013-08-15 | ||
| US14/092,539 US8926974B2 (en) | 2012-08-16 | 2013-11-27 | Methods of treating a tauopathy |
| US14/092,539 | 2013-11-27 | ||
| PCT/US2014/041553 WO2014200921A1 (en) | 2013-06-10 | 2014-06-09 | Methods of treating a tauopathy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016525502A JP2016525502A (ja) | 2016-08-25 |
| JP2016525502A5 true JP2016525502A5 (enExample) | 2017-06-29 |
| JP6446443B2 JP6446443B2 (ja) | 2018-12-26 |
Family
ID=52022687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016519574A Expired - Fee Related JP6446443B2 (ja) | 2013-06-10 | 2014-06-09 | タウオパチーの処置方法 |
Country Status (19)
| Country | Link |
|---|---|
| EP (2) | EP3760228A1 (enExample) |
| JP (1) | JP6446443B2 (enExample) |
| CN (1) | CN105339002B (enExample) |
| BR (1) | BR112015030356A2 (enExample) |
| CA (2) | CA3173775A1 (enExample) |
| CY (1) | CY1123672T1 (enExample) |
| DK (1) | DK3007726T3 (enExample) |
| EA (1) | EA039554B1 (enExample) |
| ES (1) | ES2800827T3 (enExample) |
| HR (1) | HRP20201064T1 (enExample) |
| HU (1) | HUE050485T2 (enExample) |
| LT (1) | LT3007726T (enExample) |
| MX (2) | MX370723B (enExample) |
| PL (1) | PL3007726T3 (enExample) |
| PT (1) | PT3007726T (enExample) |
| RS (1) | RS60883B1 (enExample) |
| SI (1) | SI3007726T1 (enExample) |
| SM (1) | SMT202000401T1 (enExample) |
| WO (1) | WO2014200921A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6290212B2 (ja) * | 2012-08-16 | 2018-03-07 | アイピエリアン，インコーポレイティド | タウオパチーの処置方法 |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| NZ630610A (en) | 2014-02-14 | 2019-05-31 | Ipierian Inc | Tau peptides, anti-tau antibodies, and methods of use thereof |
| TWI669314B (zh) | 2015-02-26 | 2019-08-21 | 美國禮來大藥廠 | 針對ｔａｕ之抗體及其用途 |
| EP3303386B1 (en) * | 2015-06-05 | 2024-08-28 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| US10988529B2 (en) | 2016-08-09 | 2021-04-27 | Eli Lilly And Company | Combination therapy |
| FR3058143B1 (fr) * | 2016-10-27 | 2021-03-12 | Univ Grenoble Alpes | Nanocorps anti-tau |
| CN110248959B (zh) | 2016-12-07 | 2023-06-30 | 基因泰克公司 | 抗tau抗体和使用方法 |
| AU2017373889B2 (en) * | 2016-12-07 | 2025-01-02 | Ac Immune Sa | Anti-Tau antibodies and methods of use |
| JOP20180014A1 (ar) | 2017-02-27 | 2019-01-30 | Teijin Pharma Ltd | جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه |
| CN110770253A (zh) * | 2017-06-16 | 2020-02-07 | 百时美施贵宝公司 | 用于治疗tau蛋白病的组合物和方法 |
| TWI750419B (zh) | 2017-10-16 | 2021-12-21 | 日商衛材R&D企管股份有限公司 | 抗tau抗體及其用途 |
| CA3107788A1 (en) | 2018-07-31 | 2020-02-06 | Eli Lilly And Company | Combination of anti-tau antibody and oga inhibitor for treatment of diseases characterized by aberrant tau aggregation |
| JP2022043373A (ja) * | 2018-12-28 | 2022-03-16 | 国立大学法人京都大学 | 大脳皮質細胞からのｌ１ｃａｍ陽性細胞の取得およびその細胞製剤としての使用 |
| EP3947446A1 (en) * | 2019-03-25 | 2022-02-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Treatment of taupathy disorders by targeting new tau species |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4866132A (en) | 1986-04-17 | 1989-09-12 | The Research Foundation Of State University Of New York | Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5811310A (en) * | 1986-09-30 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva Univ. | The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease |
| DE3853515T3 (de) | 1987-05-21 | 2005-08-25 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| US5256334A (en) | 1988-09-08 | 1993-10-26 | The Research Foundation Of The State University Of New York | Homogeneous radiopaque polymer-organobismuth composites |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| JP3540315B2 (ja) | 1991-09-23 | 2004-07-07 | メディカル リサーチ カウンシル | キメラ抗体の製造−組合せアプローチ |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| CA2592997A1 (en) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Pseudo-adenovirus vectors |
| US6010913A (en) | 1992-12-14 | 2000-01-04 | N.V. Innogenetics S.A. | Isolated human tau peptide |
| US5346981A (en) | 1993-01-13 | 1994-09-13 | Miles Inc. | Radiopaque polyurethanes |
| DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
| JP3532566B2 (ja) | 1993-06-24 | 2004-05-31 | エル． グラハム，フランク | 遺伝子治療のためのアデノウイルスベクター |
| JP3875990B2 (ja) | 1993-10-25 | 2007-01-31 | カンジ，インコーポレイテッド | 組換えアデノウイルスベクターおよび使用方法 |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5625048A (en) | 1994-11-10 | 1997-04-29 | The Regents Of The University Of California | Modified green fluorescent proteins |
| KR100445103B1 (ko) | 1994-12-09 | 2004-12-04 | 임페리얼 컬리지 이노베이션스 리미티드 | 유전자의동정 |
| US5939045A (en) | 1994-12-22 | 1999-08-17 | Nissan Chemical Industries, Ltd. | Organic bismuth derivatives for X-ray imaging |
| US5958713A (en) | 1995-01-31 | 1999-09-28 | Novo Nordisk A/S | Method of detecting biologically active substances by using green fluorescent protein |
| US5670477A (en) | 1995-04-20 | 1997-09-23 | Joseph F. Poduslo | Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents |
| US5968738A (en) | 1995-12-06 | 1999-10-19 | The Board Of Trustees Of The Leland Stanford Junior University | Two-reporter FACS analysis of mammalian cells using green fluorescent proteins |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| US6020192A (en) | 1996-01-18 | 2000-02-01 | University Of Florida | Humanized green fluorescent protein genes and methods |
| ATE208629T1 (de) | 1996-08-27 | 2001-11-15 | Chiron Corp | Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung |
| US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
| TW371617B (en) | 1996-10-09 | 1999-10-11 | Of Animal And Plant Health Inspection And Quarantine Council Of Agriculture Executive Yuan Bureau | Method to transplant GFP into autographa californica multiple nuclear polyhedrosis virus for inflicting pest in an attempt to detect and flow up it existence and to improve life span against UV |
| US6080849A (en) | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
| KR20010015856A (ko) | 1997-12-12 | 2001-02-26 | 마크로메드 인코퍼레이션 | 단백질 변성용으로 헤테로 작용기를 가진 별 모양의폴리(에틸렌글리콜) |
| US5985577A (en) | 1998-10-14 | 1999-11-16 | The Trustees Of Columbia University In The City Of New York | Protein conjugates containing multimers of green fluorescent protein |
| JP5247963B2 (ja) | 2000-01-24 | 2013-07-24 | インノジェネティクス・エヌ・ブイ | タウオパチーの診断 |
| GB0105924D0 (en) | 2001-03-09 | 2001-04-25 | Microscience Ltd | Promoter |
| GB0117326D0 (en) | 2001-07-16 | 2001-09-05 | Univ Aberdeen | Napthoquinone-type inhibitors of protein aggregation |
| KR100754596B1 (ko) | 2001-09-21 | 2007-09-05 | 미쯔비시 웰 파마 가부시키가이샤 | 3-치환-4-피리미돈 유도체 |
| KR20070034512A (ko) | 2004-06-18 | 2007-03-28 | 암브룩스, 인코포레이티드 | 신규 항원-결합 폴리펩티드 및 이의 용도 |
| US20090016959A1 (en) | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
| US8741260B2 (en) | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
| CN103665170A (zh) | 2008-12-05 | 2014-03-26 | 安吉奥开米公司 | 肽治疗剂轭合物及其应用 |
| US9605054B2 (en) * | 2009-02-23 | 2017-03-28 | The Board Of Trustees Of The University Of Illinois | Composition and method for treating a tauopathy |
| LT2627672T (lt) * | 2010-10-11 | 2018-12-10 | Biogen International Neuroscience Gmbh | Žmogaus antikūnai prieš tau baltymą |
| WO2012106363A2 (en) * | 2011-01-31 | 2012-08-09 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| GB201112056D0 (en) * | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
| JP6290212B2 (ja) * | 2012-08-16 | 2018-03-07 | アイピエリアン，インコーポレイティド | タウオパチーの処置方法 |
| US20140056901A1 (en) * | 2012-08-21 | 2014-02-27 | The Institute For Molecular Medicine | Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
-
2014
- 2014-06-09 HR HRP20201064TT patent/HRP20201064T1/hr unknown
- 2014-06-09 RS RS20200796A patent/RS60883B1/sr unknown
- 2014-06-09 JP JP2016519574A patent/JP6446443B2/ja not_active Expired - Fee Related
- 2014-06-09 EP EP20162335.2A patent/EP3760228A1/en not_active Withdrawn
- 2014-06-09 HU HUE14734364A patent/HUE050485T2/hu unknown
- 2014-06-09 CA CA3173775A patent/CA3173775A1/en active Pending
- 2014-06-09 CN CN201480032717.2A patent/CN105339002B/zh not_active Expired - Fee Related
- 2014-06-09 LT LTEP14734364.4T patent/LT3007726T/lt unknown
- 2014-06-09 PL PL14734364T patent/PL3007726T3/pl unknown
- 2014-06-09 ES ES14734364T patent/ES2800827T3/es active Active
- 2014-06-09 SM SM20200401T patent/SMT202000401T1/it unknown
- 2014-06-09 DK DK14734364.4T patent/DK3007726T3/da active
- 2014-06-09 SI SI201431606T patent/SI3007726T1/sl unknown
- 2014-06-09 CA CA2914768A patent/CA2914768A1/en not_active Abandoned
- 2014-06-09 PT PT147343644T patent/PT3007726T/pt unknown
- 2014-06-09 WO PCT/US2014/041553 patent/WO2014200921A1/en not_active Ceased
- 2014-06-09 BR BR112015030356A patent/BR112015030356A2/pt active Search and Examination
- 2014-06-09 MX MX2015016240A patent/MX370723B/es active IP Right Grant
- 2014-06-09 EA EA201592203A patent/EA039554B1/ru unknown
- 2014-06-09 EP EP14734364.4A patent/EP3007726B1/en active Active
-
2015
- 2015-11-25 MX MX2019015604A patent/MX2019015604A/es unknown
-
2020
- 2020-07-03 CY CY20201100614T patent/CY1123672T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016525502A5 (enExample) | ||
| HRP20201064T1 (hr) | Postupci liječenja tauopatije | |
| León et al. | Pathogenic mechanisms underlying adverse reactions induced by intravenous administration of snake antivenoms | |
| US11926660B2 (en) | Anti-ApoE antibodies | |
| JP2015530971A5 (enExample) | ||
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| JP2018502840A5 (enExample) | ||
| JP2017530722A5 (enExample) | ||
| JP2023520821A (ja) | 血液脳関門送達のための組成物および方法 | |
| JP2016526878A5 (enExample) | ||
| FI3487882T3 (fi) | Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja | |
| JP2015532592A5 (enExample) | ||
| RU2015143886A (ru) | Антитела к тау и способы применения | |
| JP2018503357A5 (enExample) | ||
| RU2018135371A (ru) | АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb | |
| AR109298A1 (es) | Anticuerpos multiepitópicos y multivalentes que tienen actividad agonista y métodos de uso | |
| JP2016529229A5 (enExample) | ||
| JP2019527194A5 (enExample) | ||
| JP2015533795A5 (enExample) | ||
| JP2011046732A5 (enExample) | ||
| JP2015504421A5 (enExample) | ||
| JP2015503909A5 (enExample) | ||
| CN112105639B (zh) | 抗PHF-tau抗体及其用途 | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| RU2018102606A (ru) | Молекулы, связывающиеся с psl pseudomonas, и пути их применения |